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Abstract 
Background: Blood biomarkers of neurovascular damage are used clinically to diagnose the presence severity or 
absence of neurological diseases, but data interpretation is confounded by a limited understanding of their depend-
ence on variables other than the disease condition itself. These include half-life in blood, molecular weight, and 
marker-specific biophysical properties, as well as the effects of glomerular filtration, age, gender, and ethnicity. To 
study these factors, and to provide a method for markers’ analyses, we developed a kinetic model that allows the 
integrated interpretation of these properties.
Methods: The pharmacokinetic behaviors of S100B (monomer and homodimer), Glial Fibrillary Acidic Protein and 
Ubiquitin C-Terminal Hydrolase L1 were modeled using relevant chemical and physical properties; modeling results 
were validated by comparison with data obtained from healthy subjects or individuals affected by neurological dis-
eases. Brain imaging data were used to model passage of biomarkers across the blood–brain barrier.
Results: Our results show the following: (1) changes in biomarker serum levels due to age or disease progression are 
accounted for by differences in kidney filtration; (2) a significant change in the brain-to-blood volumetric ratio, which 
is characteristic of infant and adult development, contributes to variation in blood concentration of biomarkers; (3) 
the effects of extracranial contribution at steady-state are predicted in our model to be less important than suspected, 
while the contribution of blood–brain barrier disruption is confirmed as a significant factor in controlling markers’ 
appearance in blood, where the biomarkers are typically detected; (4) the contribution of skin to the marker S100B 
blood levels depends on a direct correlation with pigmentation and not ethnicity; the contribution of extracranial 
sources for other markers requires further investigation.
Conclusions: We developed a multi-compartment, pharmacokinetic model that integrates the biophysical proper-
ties of a given brain molecule and predicts its time-dependent concentration in blood, for populations of varying 
physical and anatomical characteristics. This model emphasizes the importance of the blood–brain barrier as a gate-
keeper for markers’ blood appearance and, ultimately, for rational clinical use of peripherally-detected brain protein.
Keywords: Physiologically-based pharmacokinetic model, Precision medicine, Traumatic brain injury, Glomerular 
filtration, Serum markers
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Background
Peripheral biomarkers have myriad potential uses for 
prognostication, treatment and pharmacovigilance in 
many diseases, including those of neurological nature. 
For example, levels of the brain-derived glial fibrillary 
acidic protein (GFAP), S100B, tau and Ubiquitin C-Ter-
minal Hydrolase L1 (UCHL-1) in biological fluids have 
been shown to correlate with presence and severity of 
many neurological disorders. Steady-state blood levels of 
these biomarkers are measurable, albeit at low concen-
trations, and increase rapidly after head injury. The most 
common use for peripheral biomarkers has been in the 
field of traumatic brain injury (TBI). The possibility of 
using serum S100B as a diagnostic tool for patients with 
mild head injury (MHI) was first reported in 1995 [1]. It 
was first thought that S100B release was a biomarker of 
subtle brain damage after MHI, although data suggests 
that an equally relevant mechanism may involve the 
release of S100B through a disrupted blood–brain barrier 
(BBB), without necessarily involving actual cellular dam-
age [2–5]. Comparable results were obtained with GFAP 
and UCHL-1 [6] which suggests that these markers also 
appear in blood when the BBB is compromised.
The brain parenchyma is protected by a vascular bar-
rier, referred to as BBB. The system of capillaries form-
ing the human BBB has approximately 20 m2 of exchange 
surface with brain tissue, and is separated from neu-
rons by only a few microns. The BBB maintains a strict 
compartmentalization of brain-and-blood-specific 
substances through the presence of a tight-junctioned 
endothelial cell layer. During blood–brain barrier dis-
ruption (BBBD), proteins normally present in high con-
centrations in the CNS are free to diffuse into the blood 
following their concentration gradients [7]. An ideal and 
clinically significant biomarker should be: (1) present at 
low or undetectable levels in serum of normal subjects 
under steady-state conditions; (2) present in brain and 
cerebrospinal fluid (CSF) at higher concentrations than 
in blood; (3) susceptible to extravasation in the event of 
BBBD; (4) further released by brain cells in response to 
brain damage (e.g., during reactive gliosis).
Among the several reasons that made the use of brain 
biomarkers a holy grail for neurology is the minimally-
invasive nature of the process required to obtain blood 
samples. While a venipuncture is typically required, 
such a procedure is clearly less morbid than CSF sam-
pling or the use of intravascular contrast agents (e.g., 
gadolinium or iodinated contrast agents). In addition, 
imaging modalities such as computed tomography (CT) 
scans expose the patient to radiation. Last, but perhaps 
not least, is the cost differential between state-of-the-art 
medical imaging and a simple blood test.
While the advantages of peripheral biomarkers are well 
understood, their widespread use has been confounded 
by several factors including inter-individual variability 
in “reference values”, the effect of age on markers’ pres-
ence or levels, ethnic differences, etc. Many groups have 
described this variability, and most of the data presented 
so far has focused on the astrocytic protein S100B [8]. 
This biomarker has been studied for several years, and 
investigated as a tool to diagnose non-CNS conditions, 
mainly malignant melanoma [9]. Other markers are being 
investigated, and it’s very likely that a number of new 
markers will become available in the next decade. We 
hypothesize that one of the obstacles in the acceptance of 
peripheral biomarker detection as a diagnostic approach 
for neurological diseases is the lack of understanding on 
how serum biomarker levels are holistically controlled 
by other physiological functions and parameters. For 
example, it has been suggested that S100B levels directly 
depend on body mass index (BMI) [10], while others have 
suggested that the increased BBB permeability in diabetes 
or conditions associated with obesity are the underlying 
factors contributing to this variability [11]. We developed 
a computer model that mimics, for a range of biomarker 
proteins, the key physiological features (e.g., BBB perme-
ability, extracranial contribution) and pharmacokinetic 
properties (e.g., biomarker size and distribution, renal 
elimination) that contribute to changes in serum bio-
marker levels irrespective of neurological triggers.
Methods
Literature review for initial assignments of the model
The following sources were used to obtain the quantita-
tive values used as initial conditions for our model. Val-
ues for total blood volume (TBV) were calculated using 
Nadler’s formula shown in Eq. 1: 
where height and weight must be in units of meter and 
kilogram but are considered in the formula as unit-less 
quantities. Values for kidney function were acquired 
from [12]. Initial biomarker levels in brain were obtained 
from sources identified in Table 1. The values for maxi-
mal leakage of S100B and its homodimer were derived 
from our previous work [4, 11, 13]. The quantitative 
assignment of S100B levels in the human tissue of periph-
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Glomerular filtration rate (GFR) was calculated using the 
Cockcroft–Gault formula shown in Eq. 2:
where the variables A, B, exp and serum creatinine (SrCr) 
are race-and-gender-dependent, and GFRFunction ranges 
from 0 to 1 and is indicative of kidney health. Due to the 
nature of the Cockcroft–Gault formula, changing age 
does little to influence the outcome of the model; as such, 
the value of Age was standardized to 45 years.
Physiologically‑based biomarker kinetic model 
development
Our model was developed using the SimBiology exten-
sion of MatLab (MathWorks, Natick MA), and results 
were analyzed in the Origin Pro 9.0 (Northampton, MA) 
and JMP 11 (SAS) programs. Our methods were derived 
from a generic Physiologically-Based Pharmacokinetic 
(PBPK) model developed by others [14], which was fur-
ther based on a previous multi-compartment system in 
which several organs were represented with realistic 
dimensions [15, 16]. In the aforementioned model, the 
organs were connected by arterial and venous circula-
tion with appropriate hemodynamic values, also obtained 
from the literature. For the model described herein, we 
simplified this arterial-to-venous transfer of biomark-
ers by assuming a homogeneous distribution of the bio-
marker in the systemic circulation, and that the volume 
of this idealized vascular compartment was equal to the 
















for the cerebral circulation, where permeability across 
the BBB was incorporated as a governing factor to free 
diffusion of brain-specific biomarkers. This dynamic 
range theoretically extends from a biomarker diffusivity 
(cm2/s) of zero to a diffusivity that equals the concentra-
tion-driven diffusion of a given molecule in bodily flu-
ids. This spectrum of values is biologically unrealistic, 
but was established for convenience (see also Eq.  3 and 
paragraphs below). The extent of “opening” for the BBB 
was based on clinical observations (see Fig. 2b), and the 
kinetic property of molecule extravasation was based on 
empirical results (see Fig. 2a) [4, 5, 17, 18]. While there is 
a large difference between measurements based on con-
trast-enhancement versus diffusion of a molecule from 
brain to blood, we suggest that this “Radiologic Index” 
is currently the best comparative approach to model the 
behavior of a diffusible marker against clinically accept-
able means. Please note that markers’ concentrations in 
the blood were set to 0 ng/ml at the beginning of the sim-
ulation so that a kinetic progression toward steady-state 
levels could be observed.
Biological markers, as the ones modeled in this manu-
script, are present in different CNS compartments. For 
example, S100B and GFAP are expressed at high levels 
in astrocytes (but not neurons or other brain cell types) 
but can also be detected in CSF as well as in intersti-
tial fluid (ISF). Since the kinetics governing intracel-
lular-to-extracellular exchange for these biomarkers is 
poorly understood, we used clinically available data to 
assign each biomarker an initial brain concentration 
(Fig. 1). The initial assignments used reflect what can be 
Table 1 Initial parameter values used within model
Model feature Parameter Value References
Brain biomarker concentration S100b monomer (10.7 kD) 10.0 ng/ml = 1.0 nM [23, 25, 36, 37]
S100b dimer (21.0 kD) 10.0 ng/ml = 0.5 nM
GFAP (26.0 kD) 1.0 ng/ml = 0.038 nM
UCHL-1 (26.0 kD) 7.6 ng/ml = 0.292 nM
Blood–brain barrier Steady-state, newborn 10% of maximal BBBD [4, 11, 13]
Steady-state, adult 1–5% of maximal BBBD
Central nervous system Brain volume, newborn 0.42 l [38]
Brain volume, adult 1.42 l (male) 1.05 l (female) [15, 16]
Blood volume, newborn 0.28 l [39]
Blood volume, adult 6.0 l [15, 16]
Skin Skin volume, adult 7.8 l [15]
S100b in light skin 0.288 ng/ml [11]
S100b in dark skin 2.0 ng/ml
Kidneys Glomerular filtration rate GFR (ml/min) = ((A*((SrCr/B)) ^ 1.209) * (0.993 ^ Age) [12]
Coefficient A (Caucasian) 141 (male) 144 (female)
Coefficient A (African American) 163 (male) 166 (female)
Coefficient B 0.9 (male) 0.7 (female)
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measured in extracellular fluid in normal brain. In spite 
of this simplification, our approach and modeling allow 
to replicate the common features of many neurological 
diseases (i.e., gliosis) if the increase in marker’s source 
concentration can be estimated or measured. Gliosis is 
a secondary sequela of many acute injuries such as TBI, 
stroke, etc. During the gliotic process, GFAP and S100B 
are increased in astrocytes as well as in ISF and CSF.
Model background
We used available data from patients undergoing BBBD 
by osmotic means [5, 17, 18] to determine the rate of 
S100B increase in blood. The time-dependent data corre-
sponding to sudden increases in S100B for these patients 
was fitted to Eq. 3:
where time is expressed in minutes after the osmotic 
shock. For details see [5] and Fig. 2a.
Cross-validation of “goodness of BBB opening” meas-
ured by peripheral S100B and CT enhancement was 
performed as described [17, 18]. Maximal osmotic and 
bi-hemispheric BBBD was set as 100% while no effect 
of BBBD was computed as 0%. S100B was measured at 
time of imaging by contrast CT and plotted in Fig. 2b as 
the difference between post- and-pre-disruption S100B 
values in serum. In the model, we expressed the time-
dependent change in BBB permeability according to Eq. 3 
and the subsequent change in blood S100B according to 
Eq. 4. We assumed in the simulation a steady-state, phys-
iological “leak” of S100B across a healthy BBB as 1–5% of 
maximal possible hemispheric disruption, as per Eq. 4:
The relationship between molecular weight (MW) of 
a biomarker and its propensity to be filtered by the kid-
neys, referred to herein as the filtration coefficient (CF), 
was based on Eq. 5:
(3)[S100B]serum = 0.29− 0.20 ∗ 0.79
time









where the value of CF falls between 0 (no filtration) and 
1.0 (complete filtration). Empirical data used to create 
this fitted equation was obtained from [19]. A graphic 
description of the model is provided in Additional file 1: 
Figure S1.
BBB disruption in patients
All patients signed an informed consent according to 
institutional review protocols of The Cleveland Clinic 
Foundation and the Declaration of Helsinki. Eight 
patients with the histologically-proven, non-acquired 
immunodeficiency syndrome Primary Central Nervous 
System lymphoma (PCNSL) consented to participate in 
an institutional, review board-approved protocol for the 
management of this disease at the Cleveland Clinic Foun-
dation. This protocol involved the concurrent administra-
tion of intravenous chemotherapy and a treatment that 
included BBB disruption [20] followed by the instilla-
tion of intra-arterial chemotherapy (IAC). This subset of 
patients also agreed to additional blood draws for serum 
S100B sampling. The appropriate inclusion and exclusion 
of patients on this protocol was documented previously 
[21]. Specifically, these patients were treated with intra-
arterial injection of mannitol causing a temporary dis-
ruption of the BBB, followed by a selective, intra-carotid 
chemotherapeutic injection. The procedure consisted of 
the following steps: (1) patient is taken to the operating 
room and general thiopental anesthesia is induced; (2) 
catheterization of a selected intracranial artery (either 
an internal carotid or vertebral artery) is performed via 
a percutaneous, trans-femoral puncture on a given treat-
ment day; (3) mannitol (25%; osmolarity 1372) is admin-
istered intra-arterially via the catheter at a predetermined 
rate of 3–12 cc/s for 30  s; (4) after the BBB is “opened” 
with mannitol, intra-arterial methotrexate is infused. 
Immediately following delivery of chemotherapy, non-
ionic contrast dye is given intravenously; (5) the patient 
is transported, still anesthetized, for a CT scan. This step 
is essential to determine and document the extent of BBB 
opening since better disruption portends better delivery 
(See figure on next page.) 
Fig. 1 Initial assignments and assumptions for the pharmacokinetic model. The illustrations provide a region-specific grouping of all initial assign-
ments and assumptions considered in our kinetic modeling of biomarker distribution. A detailed graphic and mathematical description of the 
model is in Additional file 2: Figure S2. Parameters incorporated into the CNS a included: (1) molecular weight and concentration of biomarkers; (2) 
neonatal brain volume and volemia; (3) adult male/female brain volume and volemia; and (4) homeostatic (pre-BBBD) permeability levels across the 
BBB (see “Methods” section). Extracranial contributions to serum biomarker levels b do not significantly differ from a model whose only contribu-
tion comes from the brain. Extracranial sources of S100B were quantified using data from [11], and each organ was set to a fixed (1–5%) rate of 
marker’s transfer to blood. The corresponding bar plot shows organ-specific contribution to serum levels. The flowchart in the inset shows a simpli-
fied diagram of the skin-to-blood contribution of S100B in the pharmacokinetic model. Arterial and venous blood volumes were combined into a 
common, systemic blood compartment c and an assumption of homogeneity was employed for serum biomarker levels. The blood compartment 
was provided an initial biomarker concentration of 0 ng/ml. Passage of biomarker mass into the kidneys d was dependent on initial assignment of 
glomerular filtration rate (GFR), as calculated by the Cockroft-Gault formula for both African American (A–A) and Caucasian male and female adults. 
Neonatal kidney filtration was preset to 47 ml/min/1.73 m2 (see Table 1)
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of chemotherapeutic drugs across the barrier. Methods 
for grading the degree of BBBD and correlation of these 
grades with Hounsfield units were previously described 
[22]; degree of BBBD was graded by visual inspection as 
nil, fair, good, or excellent; (6) after the CT scan is com-
pleted the patient is awakened, extubated and monitored 
in the hospital overnight. Blood samples were drawn 
10  min prior to mannitol injection and 2–5  min after 
mannitol injection. S100B was measured on all available 
blood samples by techniques described elsewhere [5, 13]. 
A total of 102 BBBD procedures in eight patients were 
studied. The results in Fig. 1 refer to 14 procedures con-
sisting of intra-arterial chemotherapy not preceded by 
BBBD.
Fig. 2 Experimental and theoretical determination of blood–brain barrier characteristics, and quantitative assessment of the effects of biomarker 
molecular weight on modeling results. The kinetics of BBBD in this model were derived from data from previous studies that involved human 
patients receiving iatrogenic osmotic opening of the barrier. Time-dependent opening of the BBB was modeled in accordance with a, Eq. 2 which 
shows the time course of serum S100B elevation after intra-arterial infusion with 1.6 M mannitol. The extent at which serum S100B levels were 
affected by BBBD was modeled in accordance with (b, Eq. 3, see dashed red line); a radiologic scale of BBB opening shows that 0% BBBD promotes 
no change in serum S100B, while maximal BBBD causes an increase of ~0.22 ng/ml in serum S100B. Note the dashed black line indicating no change 
in S100B to show that when a BBB disruption >25%, most changes in S100B levels were positive. For details regarding procedures in a and b, see 
“Methods” section. The inset in a shows an example of contrast-enhanced CT imaging used to quantify BBBD. In this case, the hyperosmotic man-
nitol solution was perfused through the internal carotid artery (ICA). In addition to glomerular filtration rate, a biomarker’s Filtration Coefficient (CF) 
determines the rate at which a marker is cleared through the kidneys (c, Eq. 5), with proteins of higher molecular weight having a lower turnover 
rate from blood into urine. Figure d demonstrates the dependency of biomarker half-life on molecular weight
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Serum S100B measurements
Serum samples of S100B were obtained after induction 
of anesthesia, immediately prior to and immediately after 
intra-arterial mannitol infusion (Fig.  2a). At each time 
point, blood samples were collected and immediately 
centrifuged at 1200×g for 10 min, and the supernatant 
sera were stored at −80 °C. The S100B concentration was 
measured by the Sangtec 100 ELISA method (Diasorin, 
Stillwater, MN) using high and low level manufacturer-
provided controls to ensure proper assay performance. 
A total of 267 apparently healthy subjects were prospec-
tively enrolled in compliance with IRB regulations. Serum 
samples were collected in different seasons (summer and 
winter), from different regions of the USA (North, Cen-
tral, and South), and of light and dark skin color. Dark 
skin color was defined according to FDA guidance (“dark 
skinned” is defined as Black or African–American, “light 
skinned” is defined as White, Hispanic, Asian, American 
Indian, Alaska Native, Native Hawaiian, and other Pacific 
Islander).
Results
Age‑related differences in blood biomarkers dynamics
Since the model we developed encompasses several fea-
tures of human physiology that are age-and-biomarker-
dependent, we first analyzed the effects of age on serum 
values for biomarkers of varying molecular weight (MW). 
To our knowledge, data on UCHL-1 and GFAP levels in 
healthy newborns are not available, so we instead used 
S100B values which have been reported to decrease 
from an average of 0.9 to 0.3  ng/ml in the first postna-
tal months and further decrease to 0.11  ng/ml in ado-
lescence [23]. For healthy adults, S100B levels in serum 
are below 0.1–0.12 ng/ml [3, 24, 25]. Of the physiological 
variables that may contribute to different biomarker con-
centrations between newborns and adults, we focused on 
three possible, non-mutually exclusive factors: (1) GFR 
is significantly lower in the neonatal stage of develop-
ment, and does not reach fully mature levels until after 
infancy; (2) body size, and specifically the ratio of brain 
volume to volemia/body weight, is dramatically increased 
in babies; and (3) homeostatic BBB function may differ 
post-gestation compared to adulthood. The results of 
the modeling, and any discrepancy between experimen-
tal data and model results, are shown in Fig.  3a–c. The 
plot in Fig.  3a shows steady-state and BBBD-triggered 
changes in serum S100B for a newborn with a brain-to-
blood volume ratio of 1.5 (0.42:0.28  l), compared to a 
ratio of 0.2 (1.4:6.0  l) for adults. This model also incor-
porated reference values for both neonatal and adult 
GFR which have been previously reported [12, 26–28]. 
For details regarding these parameters and other initial 
assignments, see Fig. 1 and Table 1. The simulation was 
run as follows: we initially started with a level of 0  ng/
ml for serum biomarker and observed an initial progres-
sion toward steady-state, which varies based on age-
specific variables. After steady-state was established we 
simulated a maximal BBBD (see vertical dashed line in 
Fig. 3a), which gradually decreased to represent a time-
dependent recovery of BBB integrity, and the return of 
leakage rates to steady-state levels. Serum biomarker 
levels decreased to steady-state at a rate dependent upon 
kidney function and therefore the MW of the biomarker. 
Note that newborn steady-state levels of S100B prior to 
BBBD were significantly elevated compared to that of a 
healthy adult. Similarly, the extent of the maximal BBBD-
induced serum increase for S100B was exaggerated in 
the newborn. The horizontal dashed lines in Fig. 3a and 
c emphasize the strong correlation between experimen-
tal results and output of the model. Note the excellent 
agreement between predicted S100B values at pre-BBBD 
steady-state and the results of the model.
Since one of our goals was to expand this model to 
include other markers, we added a variable that takes 
into account protein excretion, at a given GFR, for differ-
ent MWs. The results are shown in Fig.  3b and c while 
Eq.  5 shows the modeling relationship used to extrapo-
late kidney filtration for a marker’s  MW. In newborn 
(Fig. 3b), the steady-state and post-BBBD values for two 
brain markers with different MWs are shown alongside 
the kinetic curves of monomeric vs. homodimeric S100B 
[29]. Note that increased MW resulted in pronounced 
increases in clearance time, which translated into longer 
persistence of the signals. Similar results were obtained in 
adults (Fig. 3c). Please note that, although neonates and 
adults were modeled using physiological values for body 
size and kidney function, the initial concentration of 
brain markers in neonates was set equal to adults. These 
results emphasize how age-related differences in steady-
state and post-BBBD serum levels of each marker may be 
explained by anatomic (e.g., brain volume) or physiologi-
cal (e.g., steady-state BBB permeability) variations.
Gender‑related differences in blood biomarker levels
This model predicted minimal physiological changes 
in serum biomarker levels between an adult male and 
female. This is consistent with previously reported data 
showing no gender-specific variations in steady-state 
levels of S100B [30]. Although the Cockroft–Gault for-
mula for estimating glomerular filtration rate provides a 
lower rate of elimination for females than males, extent 
of contribution by the brain is also decreased due to a 
smaller brain-to-blood volumetric ratio [31]. This devia-
tion from the physiology of the adult male resulted in a 
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slightly varied kinetic curve, due to reduced clearance of 
biomarkers from female subjects’ serum. The difference 
predicted by the model is not clinically relevant as gen-
der-driven differences have not been reported.
Ethnicity‑related differences in blood biomarker levels
Recent literature has demonstrated a clinically rel-
evant difference in serum S100B levels based on race 
and regional/seasonal variance, where individuals of a 
darker complexion have been reported to have higher 
steady-state S100B levels than those of lighter com-
plexion (i.e., Caucasians during summer compared to 
winter in the Northern hemisphere [32], or individuals 
of African–American (A–A) compared to Caucasian 
descent [30, 33]). It was initially believed that ethnicity 
is the main driving force for elevated S100B in African–
American subjects [30, 33]. If this were the case, based 
on available GFR data [12], our model would predict a 
lower biomarker level in this population due to increased 
clearance. Since this is obviously not the true reason for 
the observed elevations in steady-state levels, we added 
a skin compartment to the model to predict the follow-
ing: (1) the contribution of dermal tissue to S100B levels 
for a given biomarker present in dermal tissue, at steady-
state tissue-to-blood transfer rates (2% of maximal), and 
(2) sensitivity of this contribution value to changes in 
dermal biomarker tissue concentrations (Fig. 4). We also 
measured S100B in serum of 267 apparently healthy sub-
jects in different seasons (summer and winter), regions 
of the USA (North, Central, and South), and in light or 
dark skinned individuals as described in “Methods” sec-
tion. This was done to test the hypothesis that varied 
levels of sun exposure are sufficient to account for the 
differences originally attributed to ethnic factors. The 
initial assignment of skin S100B concentration in light-
skinned subjects was derived from a previous study of 
organ-specific S100B levels, which indicated that brain 
tissue has a 34.7:1 concentration ratio with skin. This 
initial value was accompanied by a set secretion rate 
equaling 2% of free diffusion for a small molecule, a rate 
Fig. 3 Predicted differences in biomarker kinetics between neonates 
and adults, based on GFR, body size, and steady-state BBB function. 
The plot shown in (a) demonstrates, for steady-state S100B levels 
in blood, a ~16-fold increase for newborns compared to adults 
(0.92 and 0.055 ng/ml, respectively). After maximal BBBD, newborns 
presented a more dramatic increase in serum S100B concentrations. 
The horizontal dashed lines in (a) show a consistency between the 
observed levels and results from prior literature, for steady-state as 
well as maximal BBBD in adults [3, 24, 40]. Figure b and c show the 
behavior for serum levels of the homodimeric form of S100B (21 kD), 
as well as GFAP (26 kD) and S100B monomer. The concentration 
profiles in a newborn b show a significantly increased steady-state 
and post-BBBD serum level for all biomarkers, compared to an adult 
(c). The differences among markers within a neonatal or adult popula-
tion was entirely attributed in our model to GFR values. The horizontal 
dashed lines in c again show consistency between model predictions 
and results from previous studies [3, 24, 40]
◂
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corresponding to that of the BBB under steady-state 
conditions.
An obvious limitation of this approach is that one 
needs to input an initial concentration for dermal 
S100B or any other organ contributing to serum lev-
els. We therefore measured levels of S100B by ELISA 
in freshly resected surgical samples from normal access 
tissue (Fig. 1) and these values were added to an appro-
priate volume of skin [14]. Only adult males were con-
sidered for this portion of the simulation. The results 
confirmed our hypothesis: when using the measured 
values of skin [S100B] and the appropriate volumet-
ric ratios, the model accurately predicted increases in 
serum S100B based on sun exposure or skin pigmen-
tation differences due to race. Note that sun exposure 
resulted in different levels of S100B even within a light 
(or dark) skinned population. Unlike in the modeling 
results presented in Fig.  3, changes in BBBD-induced 
S100B were minimally effected (not shown). This is to 
be expected, given that BBBD only effects cerebral vas-
culature permeability.
Discussion
The main outcome of this study was the implementation 
of a MatLab-based pharmacokinetic model that allows to 
study or interpret the fate and excretion, levels and half-
life of markers derived from the CNS but sampled in the 
blood compartment. A corollary set of hypotheses, which 
were largely confirmed by cross-validation of the model 
with existing data, implicated the variation of markers’ 
levels due to: (1) physiological parameters (e.g., GFR); (2) 
somatic properties (volumetric size of different organs 
during development); and (3) environmental factors such 
as sun exposure.
Strengths of the model
One of the key strengths of this model, and the results 
presented herein, is the extent to which these results can 
be validated by empirical data. These data were primar-
ily obtained from our own work but we also used find-
ings by others in the public domain. In addition, we 
used a realistic model of the human body, based on the 
success of PBPK analysis of drug AMDE [14]. In these 
models, and in the variation adopted by us, the body is 
represented as a network of intercommunicating com-
partments; each organ has an adjustable volume to 
accommodate anatomical variations, and the organs are 
interconnected by a realistic vascular tree with arteries 
and veins. However, the capillary compartment is not 
included.
The main strength and uniqueness of this approach 
resides in the clinical data we used to model perme-
ability of the blood-brain barrier. Our results are based 
on uncommon inter-arterial procedures used to treat 
brain neoplasms. For details and rationale of this pro-
cedure, see [20]. Pertinent to this effort is the fact that 
“opening” of the BBB was clinically measured at time of 
Fig. 4 Predicted differences in serum S100B levels as a result of 
skin pigmentation. a When the initial parameters shown in Fig. 2 
(insert) were used, these parameters predicted a serum S100B level of 
0.065 ng/ml for light-skinned subjects, which is comparable to previ-
ously recorded findings within this subpopulation (asterisk near axis). 
Note that we used realistic level for skin S100B, which was taken from 
our previous study and the data in Fig. 2. In order to output accurate 
serum S100B levels for dark-skinned subjects, the model required 
that we increase skin concentration of S100B to above 2.0 ng/ml, 
which resulted in a serum concentration of 0.115 ng/ml. This implies 
that any change in a subject’s skin pigmentation (e.g., tanning) will 
increase levels of S100B. This was experimentally confirmed in b 
showing the results of a comparative analysis on the effects of expo-
sure to sun. Note the significant increase in S100B after sun exposure 
regardless of whether dark skinned (Latinos, African–American 
subjects) or light skinned individuals were studied
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blood testing by contrast-enhanced CT scans. Figure 2b 
shows the quantitative relationship between radiological 
measurements of BBBD and associated changes in blood 
S100B. Please note that because of the clinical nature of 
this trial and the large number of subjects enrolled, the 
data are not as clear-cut as one desires. Human studies 
were still utilized over available data from animal stud-
ies, however, due to increased translatability and clinical 
relevance.
Another significant feature of our modeling effort is 
the presence of excretive systems. This may come as a 
surprise given that the main focus of our research is in 
neurosciences. However, the modeling results demon-
strate that one of the chief regulators of markers’ pres-
ence in blood is the level of GFR. We were able to show 
that kidney function (both physiologic and pathologic; 
Fig. 2d) also affects markers’ half-life in a size-dependent 
manner. In other words, with physiologic kidney func-
tion, half-life was linearly related to markers’ molecu-
lar size. However, when approaching kidney failure, the 
effect was overwhelmingly shifted toward markers with 
higher (over 40 kD) molecular weight. This is important 
because markers of brain and BBB damage can be very 
small (S100B, 10  kD), of intermediate size (tau, 46  kD), 
or large (autoreactive IgG, 140 kD). We underscore that 
without adjusting for molecular weight and kidney func-
tion, one may misinterpret the true clinical meaning of 
a given marker. For example, if one wishes to determine 
the delayed sequelae of a given event (e.g., stroke, TBI) 
it is best to use a marker with a longer half-life (higher 
molecular weight).
An additional aspect that we wish to discuss is the use 
of accepted values for the markers’ initial levels in the 
brain (Fig. 1a). We also modeled the relative changes in 
brain-to-blood volume due to changes in age and gen-
der, as well as extracranial biomarker sources. In the case 
of S100B, it is widely reported that skin and fat contain 
substantial levels of S100B [10, 34]. In our model we used 
measured values for fat and skin S100B content (Fig. 1b). 
By doing so, we were able to show that skin levels directly 
affect steady-state serum S100B levels, and what is more 
important, they also reproduce changes in basal S100B 
levels due to ethnicity, exposure to sun and skin complex-
ion. As in the other modeling efforts, we used real data to 
confirm or disprove the output of the model (Fig. 4). Fat 
tissue, when measured in a broad range of BMI, has been 
reported not to influence blood S100B [11]. This may 
be surprising since the measured levels of S100B in skin 
were in fact lower than levels in fat. This discrepancy can 
be explained by two mechanisms, namely the high cel-
lular turnover and death rate of dermal cells [9] and the 
poor vascularization of adipose tissue compared to der-
mal tissue [35].
In every modeling effort, the source of modeling 
inputs is essential. Despite our efforts to use meaning-
ful input values, some aspects of this approach require 
further studies to improve output accuracy. For exam-
ple, MRI is the recognized quantitative tool to measure 
BBBD and yet we used CT. This was due to the fact that, 
at the time of our experiments, not only was intraopera-
tive MRI not available, the velocity of acquisition in CT 
scanning made their use more amenable for fast-paced, 
intra-arterial procedures. Furthermore, the length of 
time required for MRI signal acquisition was inconsist-
ent with the time resolution required by the model (min-
utes, see Fig. 2a).
Another limitation of this approach is the fact that the 
transfer of intracellular markers to the extracellular space 
is not fully understood, and certainly not known for the 
biomarkers discussed herein. We used as a surrogate for 
the movements of S100B across the plasma membrane 
data from melanoma cell lines expressing high levels of 
S100B (see Additional file  1: Figure S1 and Reference 
[9]). However, since none of the markers studied or mod-
eled appear to have endocrine or exocrine functions, we 
believe it is safe to assume that their rate of intracellu-
lar-to-extracellular transfer is low in healthy tissue. By 
the same token, it is reasonable to predict that physical 
trauma will mobilize the marker from soft tissues such 
as skin and fat, and that under condition of traumatic 
events, the contribution of extracranial sources may well 
be different than at steady-state. In addition, while every 
effort was made to use available knowledge on brain and 
body development and aging, we lacked quantitative val-
ues for the brain concentration of various biomarkers in 
the newborn population.
Conclusions
In conclusion, we developed a multi-compartment, 
pharmacokinetic model that integrates the biophysi-
cal properties of a given brain molecule and pre-
dicts its time-dependent concentration in blood, 
for populations of varying physical and anatomical 
characteristics.
Additional files
Additional file 1: Figure S1. Graphic depiction of the model use in the 
simulations described herein.
Additional file 2: Figure S2. Mathematical modeling of the kinetic 
properties of biomarker release from astrocytes. The data were modeled 
using the data in [9]. The underlying assumptions made in this Figure and 
in Reference [9]: S100B release is shown in the case of cellular damage 
(symbolized by the “hole” in the plasma membrane. Leakage of S100B 
or GFAP by other means and across an intact cellular membrane has 
not been described but cannot be ruled out. Levels of S100B release are 
expressed as fM per cell/h, which can be used for future modeling efforts. 
Whether the same applies to GFAP, another astrocytic protein, is unknown.
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